Fundraising Fox
OmicsChart
Techstars '23Martinsried, DE · 2 known investors
Find your way into OmicsChart
Sign up to see every warm intro you have to OmicsChart
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OmicsChart team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vedaly provides AI, data analytics, and decision support tools for biopharma companies to integrate insights into scientific and strategic planning. The platform helps pharmaceutical and biotech teams move faster and make data-driven decisions across drug development and research.
Also known as OmicsChart GmbH · Vedaly
Founders & leadership
Investors · 2
How we know: Debiopharm Innovation Fund's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · open dataset · 5k.vc investor directory · Not right? Tell us
Company profile
researched Sep 2026OmicsChart is a biopharma data and AI company headquartered in Martinsried, Germany, that on 1 November 2025 rebranded as Vedaly to reflect an expanded scope of services and platform. Its original focus was precision oncology: harmonizing fragmented cancer data and accelerating clinical research using large-scale data and machine learning. Its flagship product, PREON, is a patient-centric cancer data, analytics and biomarker discovery platform aimed at translational cancer researchers and computational scientists.
Under the Vedaly brand the company offers three lines of work. The collaborative AI research platform lets translational and data science teams work alongside domain-grounded AI directly around live scientific evidence — datasets, analyses, figures and literature — instead of static reports, with the stated aim of improving traceability, iteration and cross-team alignment. Strategic AI and data consulting covers AI strategy, data strategy and architecture, operating models and capability building for biopharma leaders. A delivery practice provides bioinformatics, translational analytics and AI/ML development, integrating biological, clinical and real-world data and building interpretable, reproducible models, either augmenting client teams or leading delivery.
Business model
The company combines a software platform for biopharma R&D teams with advisory and hands-on delivery services, engaging clients from targeted advisory work through to full integration of its collaborative AI platform.
Traction
Public beta launch of PREON in June 2023, graduation from the Techstars Berlin 2023 Deep Tech accelerator and the PharmStars accelerator in Boston, affiliation with the Milner Therapeutics Institute network at Cambridge University, and receipt of Merck Healthcare Speed Grant and Bavarian Start?Zuschuss grant funding.
Latest developments
On 1 November 2025 the company announced it had renamed from OmicsChart to Vedaly, alongside a broadened offering spanning a collaborative AI research platform, strategic AI and data consulting, and bioinformatics/AI delivery services.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned at the intersection of translational bioinformatics software and AI/data consulting for biopharma, originally targeting precision oncology data integration.
Technology
A collaborative AI research platform that embeds domain-grounded AI into research workflows and results around live scientific evidence, plus the PREON cancer data and analytics platform for biomarker discovery, supported by bioinformatics, translational analytics and AI/ML model development across biological, clinical and real-world data.
Go-to-market
Direct engagement with biopharma R&D and translational teams via advisory projects that can expand into platform deployment; visibility built through accelerator programs (Techstars Berlin Deep Tech, PharmStars), research grants, conference presentations and institutional networks such as the Milner Therapeutics Institute.
Biopharma and pharmaceutical organizations, specifically translational research, R&D and data science teams, as well as cancer biologists and computational scientists conducting patient-centric cancer studies.
Geography
Headquartered in Martinsried, Germany, with accelerator and network ties in Berlin, Boston (USA), Cambridge (UK) and conference activity in Italy.
History
Operating as OmicsChart, the company received a Start?Zuschuss digitalization grant from the Bavarian State Ministry for Economic Affairs, Regional Development and Energy in October 2022, was selected for the Merck KGaA 2022 Research Grant Deep Dive Workshop in November 2022, and received a Merck Healthcare Speed Grant in December 2022 to investigate molecular biomarkers of homologous recombination deficiency (HRD) in cancer patients. It launched PREON in public beta in June 2023, joined the Techstars Berlin 2023 Deep Tech accelerator in October 2023 and graduated in January 2024, completed the PharmStars pharma-focused accelerator in Boston in June 2024, joined the Milner Therapeutics Institute Affiliated Companies network at Cambridge University the same month, and presented at the WMF - We Make Future 2024 conference in Italy. On 1 November 2025 it announced its renaming to Vedaly.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 10
launches, deals, and filingsThe company announced it is now called Vedaly, reflecting the expanded scope of its services and platform.
CEO Tanya Aneichyk presented the company's omics data solution at the WMF - We Make Future 2024 conference in Italy.
OmicsChart joined the Affiliated Companies network at the Milner Therapeutics Institute, Cambridge University, UK.
OmicsChart completed the PharmStars pharma-focused accelerator program, culminating in a Showcase Event in Boston, USA.
OmicsChart graduated from the Techstars accelerator program, recognized for its use of omics data in oncology research.
OmicsChart was selected for the Techstars Berlin 2023 Deep Tech accelerator program.
OmicsChart publicly launched PREON, its cancer data and biomarker discovery platform, in public beta.
OmicsChart received a Merck Healthcare Speed Grant to investigate molecular biomarkers of HRD in cancer patients.
OmicsChart was selected as one of the top runners for the Merck KGaA 2022 Research Grant.
OmicsChart received the Start?Zuschuss grant from the Bavarian State Ministry for Economic Affairs, Regional Development and Energy, which supports digitalization.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- OmicsChartomicschart.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does OmicsChart do?
- OmicsChart, rebranded Vedaly in 2025, builds a collaborative AI research platform and data/AI consulting for biopharma R&D.
- Who are OmicsChart's investors?
- OmicsChart's investors include Debiopharm Innovation Fund, Techstars.
- Where is OmicsChart headquartered?
- OmicsChart is headquartered in Martinsried, DE.